Kaiser Permanente Northern California Medical Facilities
All KPNC Facilities, California, United States
NCT Number: NCT01568879
The aim of this study is to test the effectiveness of a pharmacist-staffed, protocol-based chronic disease management program compared to patients receiving usual care in achieving a target serum uric acid level in patients with recurrent gout.
Looking for future studies?
Notify Me21 year–80 year
All sexes
Interventional
Not applicable
All KPNC Facilities, California, United States
Gout is a chronic condition with intermittent symptoms and should be managed through an outcome-based disease management approach. Unlike other common chronic conditions, strategies for population management in gout patients have not been tested. The study will identify adult members of Kaiser Permanente (KP) Northern California with a diagnosis of gout and 3 or more outpatient or Emergency Department visits for gout over a 1-year period preceding study enrollment. These patients will be randomized to either an active management group, or to usual care. The participants will be enrolled and followed over a period of 26 weeks. The primary outcome to be measured will be the attainment and maintenance of a uric acid lowering regimen targeted to achieve serum uric acid level of 6.0 mg/dl or less. The treatment protocol will use standard treatment guidelines to lower and maintain uric acid levels to less than or equal to 6.0 mg/dl (or maximum doses of uric acid lowering medications) and provide patient education and dietary counseling. Monitoring and medication management will be carried out by a licensed clinical pharmacist under the supervision of an experienced rheumatologist. Control subjects will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling, but otherwise receive usual care. The demonstration that a chronic disease management approach to gout care can improve the health and reduce morbidity in patients with gout may illuminate a simple path towards improved quality of life and reduced morbidity in this growing population of patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Three or more outpatient/ED visits in a 24-month period prior to selection for study with one of these primary visit diagnoses:
At least 2 years of continuous Kaiser Foundation Hospital Plan membership
Baseline uric acid level above 7.0mg/dl
Exclusion criteria
The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
Time frame: change from baseline at 6 months follow up
attainment and maintenance of a serum uric acid level of 6.0 mg/dl or less. The outcome will be considered positive if that level is attained and the 6 month follow up value remains at the target level.
Time frame: 0, 12, and 26 weeks
Change in Serum Creatinine
Time frame: 0, 12, and 26 weeks
Change in serum ALT (a measure of potential toxicity)
Time frame: 0, 12, and 26 weeks
Number of gout flares
Kaiser Permanente
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06235710
Arthritis, Arthritis, Rheumatoid
Brunssum, Limburg, Netherlands
View Trial DetailsNCT00855920
Acute Gout Flare, Arthritis
Birmingham, Alabama, United States
View Trial DetailsNCT00856206
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alabaster, Alabama, United States
View Trial DetailsNCT00958438
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Berlin, Germany
View Trial Details